Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Value-Based Care Topic Center

Featured

JCP Flatiron Roundtable 1 Thumbnail
Videos
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
News
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
Erin Fox, PharmD
Videos
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
News
02/29/2024

Brandon Twyford

Brandon Twyford
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care...
02/29/2024
Cancer Care Business Exchange
From Cancer Care Business Exchange
Editor in chief Winston Wong, PharmD.
Editor Insights
02/13/2024

Winston Wong, PharmD

Winston Wong, PharmD
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
Engaging Payers
02/09/2024
Lili Brillstein, MPH
Lili Brillstein, MPH, discusses key points from the 2023 Healthcare Innovations Summit held in Aspen, Colorado, regarding the barriers to implementing value-based care models for specialty care, and what can be done to overcome them and...
Lili Brillstein, MPH, discusses key points from the 2023 Healthcare Innovations Summit held in Aspen, Colorado, regarding the barriers to implementing value-based care models for specialty care, and what can be done to overcome them and...
Lili Brillstein, MPH, discusses...
02/09/2024
Journal of Clinical Pathways
David F. Lobach, MD, PhD, MS
Videos
01/25/2024

Featuring David F. Lobach, MD, PhD

Featuring David F. Lobach, MD, PhD ...
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice...
01/25/2024
Journal of Clinical Pathways
Mary E. Cooley, PhD, RN, FAAN
Videos
01/24/2024

Featuring Mary E. Cooley, PhD, RN, FAAN

Featuring Mary E. Cooley, PhD, RN, FA...
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN,...
01/24/2024
Journal of Clinical Pathways
Harlan Levine, MD
Videos
01/23/2024

Featuring Harlan Levine, MD

Featuring Harlan Levine, MD
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights...
01/23/2024
Journal of Clinical Pathways
Kianta Key
Videos
12/28/2023

Featuring Kianta Key

Featuring Kianta Key
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice...
12/28/2023
Journal of Clinical Pathways
News
10/07/2023

Brandon Twyford

Brandon Twyford
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the...
10/07/2023
Journal of Clinical Pathways

Expert Insights

JCP Flatiron Roundtable 1 Thumbnail
Videos
05/01/2024

Featuring Gordon Kuntz; Jeremy Drainville; James Hamrick, MD; Larry Shulman, MD; Bryan Loy, MD

Featuring Gordon Kuntz; Jeremy Drainv...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants discuss how to develop and implement clinical pathways at cancer centers. This includes integrating both the latest clinical evidence and payer contract requirements to develop the most efficient clinical...
In this roundtable, participants...
05/01/2024
Journal of Clinical Pathways
Erin Fox, PharmD
Videos
04/08/2024

Featuring Erin Fox, PharmD

Featuring Erin Fox, PharmD
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps health care stakeholders can take to mitigate the impact of drug shortages on cancer care.
Erin Fox, PharmD, shares steps...
04/08/2024
Journal of Clinical Pathways
Editor in chief Winston Wong, PharmD.
Editor Insights
02/13/2024

Winston Wong, PharmD

Winston Wong, PharmD
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature articles in the Journal of Clinical Pathways offered valuable insights into the most important and compelling topics in oncology and other disease areas. This blog collects the top 5 most-read articles of the year.
Throughout 2023, feature...
02/13/2024
Journal of Clinical Pathways
David F. Lobach, MD, PhD, MS
Videos
01/25/2024

Featuring David F. Lobach, MD, PhD

Featuring David F. Lobach, MD, PhD ...
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.
David F. Lobach, MD, PhD, vice...
01/25/2024
Journal of Clinical Pathways
Mary E. Cooley, PhD, RN, FAAN
Videos
01/24/2024

Featuring Mary E. Cooley, PhD, RN, FAAN

Featuring Mary E. Cooley, PhD, RN, FA...
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.
Mary E. Cooley, PhD, RN, FAAN,...
01/24/2024
Journal of Clinical Pathways
Harlan Levine, MD
Videos
01/23/2024

Featuring Harlan Levine, MD

Featuring Harlan Levine, MD
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.
Harlan Levine, MD, highlights...
01/23/2024
Journal of Clinical Pathways
Kianta Key
Videos
12/28/2023

Featuring Kianta Key

Featuring Kianta Key
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice President for GCI Health, explained the different influences and societal factors for why Black women are underrepresented in clinical trials and how the health care industry can create changes to diversify...
Kianta Key, Group Senior Vice...
12/28/2023
Journal of Clinical Pathways
Theresa Dreyer, MPH
Videos
06/30/2023

Featuring Theresa Dreyer, MPH

Featuring Theresa Dreyer, MPH
Theresa Dreyer, MPH, value-based care team lead for the Association of American Medical Colleges (AAMC), shares further insights from her ASCO 2023 presentation and discusses the benefits and challenges for academic practices participating in...
Theresa Dreyer, MPH, value-based care team lead for the Association of American Medical Colleges (AAMC), shares further insights from her ASCO 2023 presentation and discusses the benefits and challenges for academic practices participating in...
Theresa Dreyer, MPH, value-based...
06/30/2023
Journal of Clinical Pathways
Lalan Wilfong, MD.
Conference Coverage
06/13/2023
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.
At the ASCO 2023 Annual Meeting,...
06/13/2023
Journal of Clinical Pathways
Jacqlyn Riposo
Quality Outlook
06/08/2023

Jacqlyn Riposo, MBA; Tom Valuck, MD, JD

Jacqlyn Riposo, MBA; Tom Valuck, MD, ...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers for Medicare and Medicaid Services new cell and Gene Therapy Access Model proposal and recommends different ways the Center for Medicare and Medicaid Innovation can apply quality measurement to cell and gene...
This blog discusses the Centers...
06/08/2023
Journal of Clinical Pathways
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
Blog
08/07/2024
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together...
08/07/2024
Journal of Clinical Pathways
Farrukh Awan, MD
Videos
07/31/2024
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some...
07/31/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
07/29/2024
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part...
07/29/2024
Cancer Care Business Exchange
Ivy Altomare, MD
Videos
07/23/2024
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an...
07/23/2024
Journal of Clinical Pathways
Laura Bray
Videos
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Sandip Patel, MD
Videos
07/22/2024
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the...
07/22/2024
Journal of Clinical Pathways
Steve Kalloger, MSc
Videos
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
07/15/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health...
07/15/2024
Cancer Care Business Exchange
Gunjan Sharma
Interview
07/10/2024
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst...
07/10/2024
Journal of Clinical Pathways
Stephen Colvill, MBA
Conference Coverage
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways

Newsfeed

News
04/11/2024

Brandon Twyford

Brandon Twyford
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024 NCCN Annual Conference gives insight into care quality, cost dynamics, and the evolving landscape of oncologic innovation.
A study presented at the 2024...
04/11/2024
Journal of Clinical Pathways
News
02/29/2024

Brandon Twyford

Brandon Twyford
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care organizations, the National Cancer Care Alliance (NCCA) and Quality Clinical Cancer Associates (QCCA), have joined forces to create ONCare Alliance, LLC.
Two leading oncology care...
02/29/2024
Cancer Care Business Exchange
News
10/07/2023

Brandon Twyford

Brandon Twyford
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the 2023 CPC & CBEx Annual Conference featured Harlan Levine, MD, City of Hope, in a thought-provoking presentation on what "value" in value-based care really means, and how to achieve a truly patient-centered model...
The keynote session from the...
10/07/2023
Journal of Clinical Pathways
News
09/13/2022

Yvette C Terrie

Yvette C Terrie
Registration trials focused on oncology are expanding in number and are continually enrolling patients from many different countries and regions; according to findings from a recently published study, regional outcome variations occur in more...
Registration trials focused on oncology are expanding in number and are continually enrolling patients from many different countries and regions; according to findings from a recently published study, regional outcome variations occur in more...
Registration trials focused on...
09/13/2022
Journal of Clinical Pathways
News
09/01/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recent cross-sectional study of national cancer care expenditures and cancer mortality rates across 22 high-income countries indicate that although the cancer mortality rate in the US was lower than the median, the US spent...
Findings from a recent cross-sectional study of national cancer care expenditures and cancer mortality rates across 22 high-income countries indicate that although the cancer mortality rate in the US was lower than the median, the US spent...
Findings from a recent...
09/01/2022
Journal of Clinical Pathways
News
08/26/2022

Yvette C Terrie

Yvette C Terrie
Amy McKee, MD, Head of Regulatory Oncology, Parexel, and Alex Gee, Senior Director, Pricing and Market Access, Parexel, provided information about recent advancements in evidence needed to support oncology drug development and shared insights...
Amy McKee, MD, Head of Regulatory Oncology, Parexel, and Alex Gee, Senior Director, Pricing and Market Access, Parexel, provided information about recent advancements in evidence needed to support oncology drug development and shared insights...
Amy McKee, MD, Head of...
08/26/2022
Journal of Clinical Pathways
News
08/26/2022

Yvette C Terrie

Yvette C Terrie
In a recent press release, the top global life sciences company, Labcorp, announced its decision from its Board of Directors to move forward with a spinoff of the company’s wholly owned Clinical Development business to shareholders of Labcorp...
In a recent press release, the top global life sciences company, Labcorp, announced its decision from its Board of Directors to move forward with a spinoff of the company’s wholly owned Clinical Development business to shareholders of Labcorp...
In a recent press release, the...
08/26/2022
Journal of Clinical Pathways
News
08/26/2022

Yvette C Terrie

Yvette C Terrie
In a recent press release, the Centers for Medicare and Medicaid Services (CMS) announced that the average basic monthly premium for standard Medicare Part D coverage is predicted to be nearly $31.50 in 2023, a reduction of 1.8% from $32.08...
In a recent press release, the Centers for Medicare and Medicaid Services (CMS) announced that the average basic monthly premium for standard Medicare Part D coverage is predicted to be nearly $31.50 in 2023, a reduction of 1.8% from $32.08...
In a recent press release, the...
08/26/2022
Journal of Clinical Pathways
News
08/16/2022

Yvette C Terrie

Yvette C Terrie
Findings from a recent study suggest that skilled nursing facilities responded to the patient driven payment model with changes in individual occupational therapy and physical therapy utilization, but no changes in rates of discharge to the...
Findings from a recent study suggest that skilled nursing facilities responded to the patient driven payment model with changes in individual occupational therapy and physical therapy utilization, but no changes in rates of discharge to the...
Findings from a recent study...
08/16/2022
Journal of Clinical Pathways
News
07/07/2022

Ellen Kurek

Ellen Kurek
A recent article discusses oncology-specific considerations when assessing elements of value, offering some background on the nature and development of quality-adjusted life-years as a part of cost-effectiveness analyses and some of their key...
A recent article discusses oncology-specific considerations when assessing elements of value, offering some background on the nature and development of quality-adjusted life-years as a part of cost-effectiveness analyses and some of their key...
A recent article discusses...
07/07/2022
Journal of Clinical Pathways
News
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
News
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
News
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways

Interactive Features

Quiz
07/29/2021
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line...
07/29/2021
Journal of Clinical Pathways
Quiz
03/12/2021
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement